R potential on the raloxifene prodrug, raloxifene diphosphate. Int J Cancer 2008; 122: 2142?147. 29. Barkhem T, Andersson-Ross C, Hoglund M, Nilsson S. Characterization with the `estrogenicity’ of tamoxifen and raloxifene in HepG2 cells: regulation of gene expression from an ERE controlled reporter vector versus regulation of your endogenous SHBG and PS2 genes. J Steroid Biochem Mol Biol 1997; 62: 53?four. 30. Kim IY, Kim BC, Seong DH, Lee DK, Search engine optimization JM, Hong YJ et al. Raloxifene, a mixed estrogen agonist/antagonist, induces apoptosis in androgen-independent human prostate cancer cell lines. Cancer Res 2002; 62: 5365?369. 31. Kim IY, Seong DH, Kim BC, Lee DK, Remaley AT, Leach F et al. Raloxifene, a selective estrogen receptor modulator, induces apoptosis in androgen-responsive human prostate cancer cell line LNCaP via an androgen-independent pathway. Cancer Res 2002; 62: 3649?653. 32. Stuart EC, Rosengren RJ. The combination of raloxifene and epigallocatechin gallate suppresses development and induces apoptosis in MDA-MB-231 cells. Life Sci 2008; 82: 943?48. 33. Bisson WH, Koch DC, O’Donnell EF, Khalil SM, Kerkvliet NI, Tanguay RL et al. Modeling in the aryl hydrocarbon receptor (AhR) ligand binding domain and its utility in virtual ligand screening to predict new AhR ligands. J Med Chem 2009; 52: 5635?641. 34. Denison MS, Rogers JM, Rushing SR, Jones CL, Tetangco SC, Heath-Pagliuso S.N-Methylhex-5-en-1-amine Order Analysis with the aryl hydrocarbon receptor (AhR) signal transduction pathway. Curr Protoc Toxicol 2002; Chapter 4: Unit four.eight. 35. Kolluri SK, Balduf C, Hofmann M, Gottlicher M. Novel target genes on the Ah (dioxin) receptor: transcriptional induction of N-myristoyltransferase two. Cancer Res 2001; 61: 8534?539. 36. Weiss C, Kolluri SK, Kiefer F, Gottlicher M. Complementation of Ah receptor deficiency in hepatoma cells: adverse feedback regulation and cell cycle handle by the Ah receptor.Formula of 5-Bromo-4-chloro-2-methylpyrimidine Exp Cell Res 1996; 226: 154?63.PMID:33527344 37. Wang F, Zhang R, Shi S, Hankinson O. The effect of aromatic hydrocarbon receptor around the phenotype in the Hepa 1c1c7 murine hepatoma cells inside the absence of dioxin. Gene Regul Syst Biol 2007; 1: 49?6. 38. Gyorffy B, Lanczky A, Eklund AC, Denkert C, Budczies J, Li Q et al. A web based survival evaluation tool to swiftly assess the effect of 22 277 genes on breast cancer prognosis applying microarray data of 1809 sufferers. Breast Cancer Res Treat 2009; 123: 725?31. + y 39. Miha Z, Gyorffy B. Improving pathological assessment of breast cancer by employing array-based transcriptome evaluation. Microarrays 2013; two: 228?42. 40. Fernandez-Salguero PM, Hilbert DM, Rudikoff S, Ward JM, Gonzalez FJ. Aryl-hydrocarbon receptor-deficient mice are resistant to two,3,7,8-tetrachlorodibenzo-p-dioxin-induced toxicity. Toxicol Appl Pharmacol 1996; 140: 173?79. 41. Bunger MK, Glover E, Moran SM, Walisser JA, Lahvis GP, Hsu EL et al. Abnormal liver development and resistance to 2,3,7,8-tetrachlorodibenzo-p-dioxin toxicity in mice carrying a mutation inside the DNA-binding domain from the aryl hydrocarbon receptor. Toxicol Sci 2008; 106: 83?two. 42. Ma Q, Whitlock JP Jr. The aromatic hydrocarbon receptor modulates the Hepa 1c1c7 cell cycle and differentiated state independently of dioxin. Mol Cell Biol 1996; 16: 2144?150. 43. Matthews J, Gustafsson JA. Estrogen receptor and aryl hydrocarbon receptor signaling pathways. Nucl Recept Signal 2006; four: e016. 44. Gasiewicz TA, Henry EC, Collins LL. Expression and activity of aryl hydrocarbon receptors in improvement and cancer. Crit Rev Eukary.